Oligodendroglioma
Symptoms, Doctors, Treatments, Advances & More

Learn About Oligodendroglioma

View Main Condition: Brain Tumor

What is the definition of Oligodendroglioma?
Oligodendroglioma is a type of brain tumor that develops from oligodendrocytes, which are specialized cells that protect neurons (nerve cells). Oligodendroglioma can occur in the brain and spinal cord.  Oligodendrogliomas are also classified as either Grade 2 or Grade 3. Grade 2 oligodendrogliomas do not spread as aggressively as Grade 3 and are less likely to cause severe symptoms. 
What are the causes of Oligodendroglioma?
The cause of oligodendrogliomas is still unknown. However, oligodendrogliomas generally tend to be more common in adults than children. Men are also more likely to develop oligodendrogliomas than women.
What are the symptoms of Oligodendroglioma?
Symptoms for oligodendroglioma primarily depend on the size and location of the tumor. Common symptoms include seizures, headaches, short-term memory issues, personality changes, and weakness on one side of the body.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Oligodendroglioma?
Treatment for oligodendroglioma may include surgery, radiation therapy, and/or chemotherapy. Surgery to remove the tumor is generally the first step in treating oligodendroglioma. Depending on the tumor's location, surgery may be able to entirely remove smaller oligodendrogliomas. However, if a tumor is located near a sensitive area in the brain, surgery may not be possible at all. Radiation therapy often follows surgery for the treatment of oligodendrogliomas. Radiation therapy involves the use of high-energy beams, including X-rays or protons, to destroy tumor cells. Chemotherapy involves the use of drugs, either taken orally or injected through a vein, to kill tumor cells. Chemotherapy is often used in combination with radiation therapy.
Who are the top Oligodendroglioma Local Doctors?
Elite in Oligodendroglioma
Elite in Oligodendroglioma

Dana-Farber Cancer Institute, Center For Neuro-Oncology

450 Brookline Avenue, 
Boston, MA 
Languages Spoken:
English
Offers Telehealth

Patrick Wen is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Wen is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Wen is board certified in Neurology and Neuro-Oncology.

Elite in Oligodendroglioma
Oncology | Hematology Oncology
Elite in Oligodendroglioma
Oncology | Hematology Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
Languages Spoken:
English
Offers Telehealth

David Peereboom is an Oncologist and a Hematologist Oncology provider practicing medicine in Cleveland, Ohio. Dr. Peereboom is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Glioma, Astrocytoma, and Bone Marrow Aspiration. Dr. Peereboom is board certified in United Council For Neurological Subspecialties, 2008.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Oligodendroglioma
Elite in Oligodendroglioma

Northwell Health Ambulatory Surgery At The Center For Advanced Medicine

450 Lakeville Road, Entrance F, 
Lake Success, NY 
Languages Spoken:
English, Hebrew
Offers Telehealth

"Michael Schulder, MD, is the vice chair of neurosurgery at North Shore University Hospital and Long Island Jewish Medical Center. He is also the director of the Brain Tumor Center at the Institute for Neurology and Neurosurgery-which treats more than 600 patients annually-and co-director of the Center for Stereotactic Radiosurgery, where his team offers the latest treatment technologies. His research focuses on improving methods of image guidance for brain tumor surgery, and on new techniques for radiosurgery.""I've always been fascinated by the workings of the brain and how it gives rise to our thoughts, memories and personalities in ways that aren't fully understood,"" Dr. Schulder says. He attended medical school at Columbia University College of Physicians and Surgeons, and completed his residency in neurological surgery at the Albert Einstein College of Medicine. Dr. Schulder also trained in stereotactic neuro-oncology at the University of Florida and the Brigham and Women's Hospital.Dr. Schulder works with neuro-oncologists, radiation oncologists and other neurosurgeons to create evidence-based treatment plans. ""We offer close multidisciplinary collaboration to help avoid delay in seeing patients,"" he says. The team strives to offer minimally invasive treatments as often as possible.With a keen interest in neurosurgical image guidance-the use of real-time images of the brain to make procedures safer and more precise-Dr. Schulder is studying the next generation of intraoperative MRI. He runs a brain tumor clinical trials program, giving his patients ready access to innovative approaches to care. While performing complex neurosurgery is one of the most satisfying parts of Dr. Schulder's job, ""empathizing with patients and their families throughout treatment is equally fulfilling,"" he says.In addition to treating brain tumors, Dr. Schulder performs functional neurosurgery to manage pain conditions like trigeminal neuralgia, and movement disorders including essential tremor and Parkinson's disease. He is the program director of neurosurgical residency training at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Schulder is active in organized neurosurgery, where among other offices he is past president of the World Society for Stereotactic and Functional Neurosurgery, director-at-large of the American Association of Neurological Surgeons, and historian of the American Academy Neurological Surgery.". Dr. Schulder is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Oligodendroglioma, Gamma Knife Radiosurgery, and Awake Craniotomy. Dr. Schulder is board certified in American Board Of Neurological Surgery.

What is the outlook (prognosis) for Oligodendroglioma?
The prognosis for oligodendroglioma is very good with current treatments. When the tumor can be removed, survival rates are over 90%. If the tumor can not be removed but radiation therapy is used, survival rates are between 80-90%.
How do I prevent Oligodendroglioma?
There is no known way to prevent oligodendrogliomas. However, if you develop any symptoms common to oligodendroglioma, it is recommended to make an appointment with your doctor to be properly diagnosed.
What are the latest Oligodendroglioma Clinical Trials?
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Summary: This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma

Summary: This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or G...

What are some Advocacy Organizations?
keep-punching-brain-cancer

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.